These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26799200)

  • 1. Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation.
    Kachroo S; Hamilton M; Liu X; Pan X; Brixner D; Marrouche N; Biskupiak J
    Am J Manag Care; 2016 Jan; 22(1):e1-8. PubMed ID: 26799200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
    Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.
    Spivey CA; Qiao Y; Liu X; Mardekian J; Parker RB; Phatak H; Claflin AB; Kachroo S; Abdulsattar Y; Chakrabarti A; Wang J
    J Manag Care Spec Pharm; 2015 Jul; 21(7):596-606. PubMed ID: 26108384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
    Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
    Lutsey PL; Norby FL; Ensrud KE; MacLehose RF; Diem SJ; Chen LY; Alonso A
    JAMA Intern Med; 2020 Feb; 180(2):245-253. PubMed ID: 31764956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
    Lip GYH; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Phatak H
    PLoS One; 2018; 13(4):e0195950. PubMed ID: 29709012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics, Patterns of Use, and incidence of Adverse Events in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants in Colombia.
    Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Mesa A; Castaño-Gamboa N; Valladales-Restrepo LF; Machado-Alba JE
    Vasc Health Risk Manag; 2023; 19():157-167. PubMed ID: 37008594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
    Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
    Coleman CI; Tangirala M; Evers T
    PLoS One; 2016; 11(6):e0157769. PubMed ID: 27327275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
    Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
    J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin.
    Datar M; Crivera C; Rozjabek H; Abbass IM; Xu Y; Pasquale MK; Schein JR; Andrews GA
    Am J Health Syst Pharm; 2019 Feb; 76(5):275-285. PubMed ID: 30698654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
    Lip GYH; Keshishian AV; Kang AL; Dhamane AD; Luo X; Li X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig S
    J Intern Med; 2021 Jan; 289(1):42-52. PubMed ID: 32602228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.
    Willey V; Franchino-Elder J; Fu AC; Wang C; Sander S; Tan H; Kraft E; Jain R
    BMJ Open; 2018 Jun; 8(6):e020676. PubMed ID: 29961012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism.
    Chan YH; Wu LS; See LC; Liu JR; Chang SH; Chao TF; Yeh YH; Kuo CT; Lee HF; Lip GYH
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32009154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.